Based on the link between CTLA4 and IDO1, a rational therapeutic consequence of this observation is to combine imatinib with an anti-CTLA4 approach in GIST, which is currently tested in a clinical trial (30). Here, CTLA4 is linked to gastrointestinal stromal tumor.